I-BET151 - CAS 1300031-49-5
Catalog number: B0084-457872
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C23H21N5O3
Molecular Weight:
415.453
COA:
Inquire
Targets:
BET Bromodomain
Description:
I-BET151, also known as GSK1210151A, is a BET bromodomain inhibitor, which blocks recruitment of BET to chromatin. I-BET151 (GSK1210151A) shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine in vivo endotoxaemia model.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-457872 25 mg $199 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
BET bromodomain inhibitor
Purity:
≥ 98%
Appearance:
Off-White Solid
Synonyms:
GSK1210151A; 7-(3,5-Dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]quinolin-2-one
MSDS:
Inquire
Melting Point:
273-277°C
InChIKey:
VUVUVNZRUGEAHB-CYBMUJFWSA-N
InChI:
InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1
Canonical SMILES:
CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC
1.Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome.
Schulz D1, Mugnier MR1, Paulsen EM2, Kim HS1, Chung CW3, Tough DF4, Rioja I4, Prinjha RK4, Papavasiliou FN1, Debler EW2. PLoS Biol. 2015 Dec 8;13(12):e1002316. doi: 10.1371/journal.pbio.1002316. eCollection 2015.
Trypanosoma brucei, the causative agent of African sleeping sickness, is transmitted to its mammalian host by the tsetse. In the fly, the parasite's surface is covered with invariant procyclin, while in the mammal it resides extracellularly in its bloodstream form (BF) and is densely covered with highly immunogenic Variant Surface Glycoprotein (VSG). In the BF, the parasite varies this highly immunogenic surface VSG using a repertoire of ~2500 distinct VSG genes. Recent reports in mammalian systems point to a role for histone acetyl-lysine recognizing bromodomain proteins in the maintenance of stem cell fate, leading us to hypothesize that bromodomain proteins may maintain the BF cell fate in trypanosomes. Using small-molecule inhibitors and genetic mutants for individual bromodomain proteins, we performed RNA-seq experiments that revealed changes in the transcriptome similar to those seen in cells differentiating from the BF to the insect stage.
2.Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons.
Li X1, Zuo X2, Jing J3, Ma Y4, Wang J1, Liu D2, Zhu J1, Du X1, Xiong L4, Du Y1, Xu J1, Xiao X2, Wang J2, Chai Z5, Zhao Y6, Deng H7. Cell Stem Cell. 2015 Aug 6;17(2):195-203. doi: 10.1016/j.stem.2015.06.003.
Recently, direct reprogramming between divergent lineages has been achieved by the introduction of regulatory transcription factors. This approach may provide alternative cell resources for drug discovery and regenerative medicine, but applications could be limited by the genetic manipulation involved. Here, we show that mouse fibroblasts can be directly converted into neuronal cells using only a cocktail of small molecules, with a yield of up to >90% being TUJ1-positive after 16 days of induction. After a further maturation stage, these chemically induced neurons (CiNs) possessed neuron-specific expression patterns, generated action potentials, and formed functional synapses. Mechanistically, we found that a BET family bromodomain inhibitor, I-BET151, disrupted the fibroblast-specific program, while the neurogenesis inducer ISX9 was necessary to activate neuron-specific genes. Overall, our findings provide a "proof of principle" for chemically induced direct reprogramming of somatic cell fates across germ layers without genetic manipulation, through disruption of cell-specific programs and induction of an alternative fate.
3.Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A1, Caputo V1, Karadimitris A2. Ther Adv Hematol. 2015 Jun;6(3):128-41. doi: 10.1177/2040620715576662.
Post-translational modifications of the nucleosomal histone proteins orchestrate chromatin organization and gene expression in normal and cancer cells. Among them, the acetylation of N-terminal histone tails represents the fundamental epigenetic mark of open structure chromatin and active gene transcription. The bromodomain and extra-terminal (BET) proteins are epigenetic readers which utilize tandem bromodomains (BRD) modules to recognize and dock themselves on the acetylated lysine tails. The BET proteins act as scaffolds for the recruitment of transcription factors and chromatin organizers required in transcription initiation and elongation. The recent discovery of small molecules capable of blocking their lysine-binding pocket is the first paradigm of successful pharmacological inhibition of epigenetic readers. JQ1 is a prototype benzodiazepine molecule and a specific BET inhibitor with antineoplastic activity both in solid tumours and haematological malignancies.
4.An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G1, Kula A2, Bouchat S2, Fujinaga K3, Corazza F4, Ait-Ammar A5, Delacourt N2, Melard A6, Kabeya K7, Vanhulle C2, Van Driessche B2, Gatot JS8, Cherrier T9, Pianowski LF10, Gama L11, Schwartz C5, Vila J2, Burny A2, Clumeck N7, Moutschen M12, De Wit S PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063. eCollection 2015.
The persistence of latently infected cells in patients under combinatory antiretroviral therapy (cART) is a major hurdle to HIV-1 eradication. Strategies to purge these reservoirs are needed and activation of viral gene expression in latently infected cells is one promising strategy. Bromodomain and Extraterminal (BET) bromodomain inhibitors (BETi) are compounds able to reactivate latent proviruses in a positive transcription elongation factor b (P-TEFb)-dependent manner. In this study, we tested the reactivation potential of protein kinase C (PKC) agonists (prostratin, bryostatin-1 and ingenol-B), which are known to activate NF-κB signaling pathway as well as P-TEFb, used alone or in combination with P-TEFb-releasing agents (HMBA and BETi (JQ1, I-BET, I-BET151)). Using in vitro HIV-1 post-integration latency model cell lines of T-lymphoid and myeloid lineages, we demonstrated that PKC agonists and P-TEFb-releasing agents alone acted as potent latency-reversing agents (LRAs) and that their combinations led to synergistic activation of HIV-1 expression at the viral mRNA and protein levels.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related BET Bromodomain Products


CAS 755038-02-9 BI-2536

BI-2536
(CAS: 755038-02-9)

BI-2563 is a small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arr...

CAS 919973-83-4 OF-1

OF-1
(CAS: 919973-83-4)

OF-1 is the potent and selective BRPF (BRomodomain and PHD Finger containing) inhibitor with Kd values 100 nM, 500 nM, and 2.4 μM for BRPF1B, BRPF2, and BRPF3, ...

CAS 2018300-62-2 TPOP146

TPOP146
(CAS: 2018300-62-2)

TPOP146 is a potent and selective CBP/P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM and 5.02 μM for CBP and BRD4. TPOP146 targets the CBP br...

CAS 936091-14-4 TG101209

TG101209
(CAS: 936091-14-4)

TG101209 is a novel and potent JAK2 inhibitor. The induction of cytotoxicity was associated with inhibition of cell cycle progression and induction of apoptosi...

CAS 1800340-40-2 BMS-986158

BMS-986158
(CAS: 1800340-40-2)

BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins with potential antineoplastic activity.

Olinone
(CAS: 1770789-37-1)

Olinone, a pyridoindol derivative, has been found to be an BET Bromodomain inhibitor and could be probably useful in sorts of biological studies.

CAS 1395084-25-9 MS436

MS436
(CAS: 1395084-25-9)

MS436 exhibits low nanomolar affinity with preference for the first bromodomain over the second.

BET-BAY 002
(CAS: 1588521-78-1)

BET-BAY 002 is a potent BET inhibitor with strong in vitro and in vivo activities in AML and MM models, and with excellent pharmacokinetic properties.

CAS 1260907-17-2 GSK525762

GSK525762
(CAS: 1260907-17-2)

GSK525762A, also known as I-BET-762 and GSK525762, is a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing pr...

CAS 936091-26-8 TG101348

TG101348
(CAS: 936091-26-8)

INCB-057643

INCB-057643 is a novel inhibitor of bromodomain and extra-terminal motif (BET) undergoing a phase I/II clinical trial for the advanced malignancy therapy. The s...

GSK 525768A
(CAS: 1260530-25-3)

GSK 525768A is a enantiomer analogue of GSK 525762A which is a BET family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts...

GSK2801
(CAS: 1619994-68-1)

GSK2801 is a A Selective Chemical Probe for BAZ2B/A bromodomains. BAZ2A/B belong to a family of ubiquitously expressed bromodomain containing proteins.probes/GS...

I-BRD9
(CAS: 1714146-59-4)

I-BRD9, as a selective cell active chemical probe for BRD9 (pIC50 = 7.3), it exhibits 200-fold selectivity for bromodomain containing protein 9 over the highly ...

CPI-637
(CAS: 1884712-47-3)

CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respect...

CAS 1869912-40-2 AZD5153 6-Hydroxy-2-naphthoic acid

AZD5153 6-Hydroxy-2-naphthoic acid
(CAS: 1869912-40-2)

AZD5153 6-Hydroxy-2-naphthoic acid, a 6-hydroxy-2-naphthoic acid salt of AZD-5153, is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor p...

CAS 1883429-22-8 BI-9564

BI-9564
(CAS: 1883429-22-8)

BI-9564 is a potent and selective inhibitor of BRD9 and BRD7 bromodomains (Kds = 14.1 and 239 nM; IC50s = 75 nM and 3.4 µM, respectively), with selectivity for ...

CAS 1923851-49-3 GSK9311

GSK9311
(CAS: 1923851-49-3)

GSK9311 is a potent and selective inhibitor of the BRPF bromodomain (pIC50= 6.0 and 4.3 for BRPF1 and BRPF2, respectively).

BET bromodomain inhibitor
(CAS: 1505453-59-7)

An BET bromodomain inhibitor can be used for the treatment of hematologic malignancies. It binds BET proteins to suppress the interaction between these proteins...

CPI-0610
(CAS: 1380087-89-7)

CPI-0610, a benzazepine derivative, has been found to influence tumor cell growth at some extent by acting as a BET bromodomain inhibitor. IC50: < 500 nM for BR...

Chemical Structure

CAS 1300031-49-5 I-BET151

Quick Inquiry

Verification code

Featured Items